...
首页> 外文期刊>Diabetes/metabolism research and reviews >The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese.
【24h】

The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese.

机译:锌转运蛋白8自身抗体(ZnT8A)对中国1型糖尿病的诊断价值。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Zinc transporter-8 (ZnT8) was recently identified as a novel autoantigen in human type 1 diabetes (T1D). Autoantibody to ZnT8 (ZnT8A) was detected in up to 80% of patients with new-onset T1D and 26% of patients with T1D otherwise classified as negative on the basis of existing markers. As no data of ZnT8A in Chinese have been reported, we aim to evaluate the utility of ZnT8A for diagnosis of autoimmune T1D in Chinese relative to other autoantibody markers. METHODS: Radioligand binding assays were performed on 539 T1D sera using human ZnT8 carboxyterminal 325Arg construct or a dimer incorporating 325Arg and 325Trp alongside antibodies to glutamic acid decarboxylase (GADA) or insulinoma-associated protein 2 (IA-2A). The antigenic specificity was analysed in the context of clinical characteristics of the patients. RESULTS: ZnT8A were present in 24.1% (130 of 539) of patients with T1D versus 1.8% (10 of 555; P < 0.001) in type 2 diabetes. At diagnosis, ZnT8A and IA-2A were less prevalent in Chinese subjects with T1D than in Caucasian populations (both P < 0.001) but similar to Japanese. The diagnostic sensitivity of combined GADA, IA-2A and ZnT8A measurements reached 65.5% with ZnT8A detected in 13.5% (29 of 215) of GADA and/or IA-2A-negative subjects. ZnT8A prevalence was lower in older and fatter patients. ZnT8A+ alone patients were distinguished from Ab- ones (P < 0.05-0.001) on the basis of higher insulin requirement and lower systolic blood pressure level. CONCLUSION: ZnT8A is an independent marker for T1D in Chinese and combined with GADA and IA-2A enhances diagnostic sensitivity. ZnT8A may be associated with different clinical phenotypes than GADA or IA-2A.
机译:背景:锌转运蛋白8(ZnT8)最近被鉴定为人类1型糖尿病(T1D)中的一种新型自身抗原。在高达80%的新发T1D患者和26%的T1D患者中检测到ZnT8自身抗体(ZnT8A),否则根据现有标记将其分类为阴性。由于尚未报道中文ZnT8A的数据,因此我们旨在评估ZnT8A相对于其他自身抗体标记物在中文自身免疫性T1D诊断中的应用。方法:使用人ZnT8羧基末端325Arg构建体或掺有325Arg和325Trp的二聚体以及针对谷氨酸脱羧酶(GADA)或胰岛素瘤相关蛋白2(IA-2A)的抗体,对539 T1D血清进行了放射性配体结合测定。在患者的临床特征的背景下分析了抗原特异性。结果:ZnT8A在2型糖尿病患者中占24.1%(539例中的130例),而1.8%(555例中的10例; P <0.001)存在。在诊断时,中国患有T1D的受试者中ZnT8A和IA-2A的流行率低于白种人(P <0.001),但与日本人相似。 GADA,IA-2A和ZnT8A组合测量的诊断敏感性达到65.5%,在13.5%(215个中的29个)的GADA和/或IA-2A阴性受试者中检测到ZnT8A。老年和肥胖患者中ZnT8A的患病率较低。基于较高的胰岛素需求量和较低的收缩压水平,单独使用ZnT8A +的患者可与Ab-的患者区分开(P <0.05-0.001)。结论ZnT8A是中国人T1D的独立标志物,与GADA和IA-2A联合使用可提高诊断敏感性。 ZnT8A可能与GADA或IA-2A的临床表型不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号